Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The study hypothesis is that low-dose computed tomography (LDCT) coupled with artificial intelligence by deep learning would generate imaging biomarkers linked to the patient's short- and medium-term prognosis. The purpose of this study is to rapidly make available an early decision-making tool (from the first hospital consultation of the patient with symptoms related to SARS-CoV-2) based on the integration of several biomarkers (clinical, biological, imaging by thoracic scanner) allowing both personalized medicine and better anticipation of the patient's evolution in terms of care organization.
Description: Dead/alive
Measure: Vital status Time: Day 8Description: Yes/no
Measure: Patient requiring more than 3 liters of oxygen to maintain a saturation >95% (intensive care unit or resuscitation department) Time: Day 8Description: % ground glass and condensation calculated by deep learning
Measure: Percentage of lung affected on CT Time: Day 0Description: % calculated by deep learning
Measure: Percentage of lung affected by ground glass opacity on scan Time: Day 0Description: % calculated by deep learning
Measure: Percentage of lung affected by condensation on scan Time: Day 0Description: Dead/alive
Measure: Vital status Time: Day 16Description: Dead/alive
Measure: Vital status Time: Day 30Description: Days
Measure: Length of hospitalization Time: Maximum 30 daysDescription: Yes/no
Measure: rehospitalization Time: Day 30Description: Days
Measure: Duration of intubation Time: Day 30Description: % ground glass and condensation calculated by deep learning
Measure: Percentage of lung affected on CT Time: Day 16Description: % calculated by deep learning
Measure: Percentage of lung affected by ground glass opacity on scan Time: Day 16Description: % calculated by deep learning
Measure: Percentage of lung affected by condensation on scan Time: Day 16Description: Speed of image loading and image processing depending of brand of scanner
Measure: Software operating time Time: End of study (August 2020)Description: mg/L
Measure: C-reactive protein levels Time: Admission Day 0Description: U/L
Measure: lactate dehydrogenase Time: Admission Day 0Description: g/L
Measure: lymphocytemia Time: Admission Day 0Description: µg/L
Measure: D Dimers level Time: Admission Day 0Description: Days
Measure: Time until onset of symptoms Time: Admission Day 0Description: Hours
Measure: Time between RT-PCR positive results and first scan Time: Admission Day 0Description: Years
Measure: Age Time: Admission Day 0Description: Yes/no:
Measure: BMI> 30 Time: Admission Day 0Description: Yes/no: hypertension, coronary artery disease, congestive heart failure, cardiac arrhythmia
Measure: Medical history of cardiovascular disease Time: Admission Day 0Description: Yes/no
Measure: Diabetes Time: Admission Day 0Description: Yes/no: Chronic obstructive pulmonary disease, chronic respiratory failure
Measure: Medical history of respiratory disease Time: Admission Day 0Description: Yes/no: steroid use, pre-existing immunological condition, current chemotherapy for cancer
Measure: Medical history of immunosuppressed condition Time: Admission Day 0Description: Yes/no:
Measure: Current or previous history of smoking Time: Admission Day 0Description: Deep learning algorithm
Measure: Calculate a prognostic score from clinical, biological and CT parameters Time: Day 8Description: Deep learning algorithm
Measure: Calculate a prognostic score from clinical and biological parameters only Time: Day 8Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports